Juan Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Du has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Haiyan Shi
Department of Clinical Medicine , Medical College of Yan’an University , Yan’an , Shaanxi , China
4 shared publicationsHuahua Zhang
Department of Clinical Medicine , Medical College of Yan’an University , Yan’an , Shaanxi , China
4 shared publicationsXiaoyong Huang
Department of Clinical Medicine , Medical College of Yan’an University , Yan’an , Shaanxi , China
4 shared publicationsYuna Jia
Department of Clinical Medicine , Medical College of Yan’an University , Yan’an , Shaanxi , China
4 shared publicationsJie Chen
Department of Clinical Medicine , Medical College of Yan’an University , Yan’an , Shaanxi , China
3 shared publicationsChangda Lei
Department of Gastroenterology, Ninth Hospital of Xi ’an, Xi’an, China
2 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 27 (1) , 2641263
Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma
1. Surgery, radiation, chemotherapy, and targeted therapy are the standard treatments for ESCC.1 Survival prospects for individuals with advanced ESCC have improved dramatically as neoadjuvant immu...
- 11 March 2026
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 27 (1) , 2641263
Open AccessResearch progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma
1. Surgery, radiation, chemotherapy, and targeted therapy are the standard treatments for ESCC.1 Survival prospects for individuals with advanced ESCC have improved dramatically as neoadjuvant immu...
- Open Access
- 1 June 2023
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 17 (3) , 124-135
miR-30c-2-3p suppresses the proliferation of human renal cell carcinoma cells by targeting TOP2A
Background: The ambiguity of renal cell carcinoma (RCC) symptoms hinders early diagnosis, thereby contributing to high mortality rates. By attaching to the 3′-untranslated region (UTR) of the target gene, microRNAs (miRNAs) exert significant control over the expression of genes. Objectives: To investigate the influence of miR-30c-2-3p and DNA topoisomerase II alpha (TOP2A) on RCC growth and the mechanisms underlying the regulation of its expression. Methods: The expression of miRNA-30c-2-3p and TOP2A in RCC cells was examined using quantitative real-time polymerase chain reaction (qRT-PCR). MiR-30c-2-3p mimics, its inhibitors, and controls, as well as TOP2A short hairpin RNA (shRNA) and controls, were used to transfect the human RCC cell lines 786-O, Caki-1, and ACHN. Additionally, the roles of miRNA-30c-2-3p and TOP2A in the growth of RCC were evaluated using the cell counting kit (CCK)-8 test, colony formation assay, apoptosis analysis, and Western blotting. Meanwhile, binding of miRNA-30c-2-3p and TOP2A was verified using dual-luciferase reporter assays and Western blotting. Results: miR-30c-2-p is underexpressed in RCC cells. Overexpression of miR-30c-2-p promotes apoptosis and inhibits proliferation of ACHN, Caki-1, and 786-O cells. miR-30c-2-3p targets TOP2A, which is elevated in RCC tissues and cells, whereas TOP2A silencing inhibits the proliferation ability of RCC cells. The miRNA-30c-2-3p inhibitor compromises TOP2A shRNA-induced apoptosis of RCC. RCC cells cotransfected with miRNA-30c-2-3p inhibitors and TOP2A shRNAs have a higher proliferation rate than those transfected with only TOP2A shRNAs. Conclusions: Collectively, our results verify that miRNA-30c-2-3p has a tumor suppressor property. miRNA-30c-2-3p inhibits the proliferation of RCC through regulation of TOP2A. The data provide a viable therapeutic target for RCC.
- 1 June 2023
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 17 (3) , 124-135
Open AccessmiR-30c-2-3p suppresses the proliferation of human renal cell carcinoma cells by targeting TOP2A
Background: The ambiguity of renal cell carcinoma (RCC) symptoms hinders early diagnosis, thereby contributing to high mortality rates. By attaching to the 3′-untranslated region (UTR) of the target gene, microRNAs (miRNAs) exert significant control over the expression of genes. Objectives: To investigate the influence of miR-30c-2-3p and DNA topoisomerase II alpha (TOP2A) on RCC growth and the mechanisms underlying the regulation of its expression. Methods: The expression of miRNA-30c-2-3p and TOP2A in RCC cells was examined using quantitative real-time polymerase chain reaction (qRT-PCR). MiR-30c-2-3p mimics, its inhibitors, and controls, as well as TOP2A short hairpin RNA (shRNA) and controls, were used to transfect the human RCC cell lines 786-O, Caki-1, and ACHN. Additionally, the roles of miRNA-30c-2-3p and TOP2A in the growth of RCC were evaluated using the cell counting kit (CCK)-8 test, colony formation assay, apoptosis analysis, and Western blotting. Meanwhile, binding of miRNA-30c-2-3p and TOP2A was verified using dual-luciferase reporter assays and Western blotting. Results: miR-30c-2-p is underexpressed in RCC cells. Overexpression of miR-30c-2-p promotes apoptosis and inhibits proliferation of ACHN, Caki-1, and 786-O cells. miR-30c-2-3p targets TOP2A, which is elevated in RCC tissues and cells, whereas TOP2A silencing inhibits the proliferation ability of RCC cells. The miRNA-30c-2-3p inhibitor compromises TOP2A shRNA-induced apoptosis of RCC. RCC cells cotransfected with miRNA-30c-2-3p inhibitors and TOP2A shRNAs have a higher proliferation rate than those transfected with only TOP2A shRNAs. Conclusions: Collectively, our results verify that miRNA-30c-2-3p has a tumor suppressor property. miRNA-30c-2-3p inhibits the proliferation of RCC through regulation of TOP2A. The data provide a viable therapeutic target for RCC.
- 13 May 2023
- Published by Elsevier in Experimental Cell Research
- Vol. 429 (2) , 113629
ADAMDEC1 induces EMT and promotes colorectal cancer cells metastasis by enhancing Wnt/β-catenin signaling via negative modulation of GSK-3β
- 13 May 2023
- Published by Elsevier in Experimental Cell Research
- Vol. 429 (2) , 113629
ADAMDEC1 induces EMT and promotes colorectal cancer cells metastasis by enhancing Wnt/β-catenin signaling via negative modulation of GSK-3β
- Open Access
- 3 March 2023
- Published by Springer Nature in BMC Molecular and Cell Biology
- Vol. 24 (1) , 1-12
RPL11 promotes non-small cell lung cancer cell proliferation by regulating endoplasmic reticulum stress and cell autophagy
Background: Abnormal biogenesis and ribosome free function of ribosomal proteins (RPs) is important for tumorgenesis and development. Ribosomal protein L11 (RPL11) is a component of ribosomal 60 S large subunit with different roles in different cancers. Here, we aimed to unravel the role of RPL11 in non-small cell lung cancer (NSCLC), especially those affecting cell proliferation. Methods: RPL11 expression in NCI-H1650, NCI-H1299, A549 and HCC827 and normal lung bronchial epithelial cells HBE was detected using western blotting. The function of RPL11 in NSCLC cells were determined by investigating cell viablity, colony formation and cell migration. Mechanism expoloration of RPL11 effect on NSCLC cells proliferation was explored using flow cytometry, and the effect on autophagy was investigated by the additon of autophagy inhibitor chloroquine (CQ) and endoplasmic reticulum stress (ERS) inhibitor tauroursodeoxycholic acid (TUDCA). Results: RPL11 was highly expressed in NSCLC cells. Extopic expression of RPL11 promoted NCI-H1299 and A549 cells proliferation, and migration, and promoted the transition from the G1 phase to the S phase of the cell cycle. Small RNA interference of RPL11 (siRNA) suppressed NCI-H1299 and A549 cells proliferation and migration and arrested the cell cycle in G0/G1 phase. Moreover, RPL11 promoted NSCLC cell proliferation by modulating autophagy and ERS. Expression levels of autophagy and ERS markers were induced by RPL11 overexpression and inhibited by siRPL11. CQ partially suppressed RPL11-induced A549 and NCI-H1299 proliferation: CQ addition reduced RPL11-induced cells viability and clone numbers and reversed the cell cycle process. ERS inhibitor (TUDCA) partially reversed RPL11-induced autophagy. Conclusion: Taken together, RPL11 has a tumor-promoting role in NSCLC. It promotes the cell proliferation of NSCLC cells by regulating ERS and autophagy.
- 3 March 2023
- Published by Springer Nature in BMC Molecular and Cell Biology
- Vol. 24 (1) , 1-12
Open AccessRPL11 promotes non-small cell lung cancer cell proliferation by regulating endoplasmic reticulum stress and cell autophagy
Background: Abnormal biogenesis and ribosome free function of ribosomal proteins (RPs) is important for tumorgenesis and development. Ribosomal protein L11 (RPL11) is a component of ribosomal 60 S large subunit with different roles in different cancers. Here, we aimed to unravel the role of RPL11 in non-small cell lung cancer (NSCLC), especially those affecting cell proliferation. Methods: RPL11 expression in NCI-H1650, NCI-H1299, A549 and HCC827 and normal lung bronchial epithelial cells HBE was detected using western blotting. The function of RPL11 in NSCLC cells were determined by investigating cell viablity, colony formation and cell migration. Mechanism expoloration of RPL11 effect on NSCLC cells proliferation was explored using flow cytometry, and the effect on autophagy was investigated by the additon of autophagy inhibitor chloroquine (CQ) and endoplasmic reticulum stress (ERS) inhibitor tauroursodeoxycholic acid (TUDCA). Results: RPL11 was highly expressed in NSCLC cells. Extopic expression of RPL11 promoted NCI-H1299 and A549 cells proliferation, and migration, and promoted the transition from the G1 phase to the S phase of the cell cycle. Small RNA interference of RPL11 (siRNA) suppressed NCI-H1299 and A549 cells proliferation and migration and arrested the cell cycle in G0/G1 phase. Moreover, RPL11 promoted NSCLC cell proliferation by modulating autophagy and ERS. Expression levels of autophagy and ERS markers were induced by RPL11 overexpression and inhibited by siRPL11. CQ partially suppressed RPL11-induced A549 and NCI-H1299 proliferation: CQ addition reduced RPL11-induced cells viability and clone numbers and reversed the cell cycle process. ERS inhibitor (TUDCA) partially reversed RPL11-induced autophagy. Conclusion: Taken together, RPL11 has a tumor-promoting role in NSCLC. It promotes the cell proliferation of NSCLC cells by regulating ERS and autophagy.
- Open Access
- 12 December 2022
- Published by Springer Nature in Research Square
RPL11 promotes non-small cell lung cancer cell proliferation via regulating endoplasmic reticulum stress and cell autophagy
Background Abnormal ribosomal proteins (RPs) biogenesis and function works importantly in tumorigenesis and development. RPL11 is a component of ribosomal 60S large subunit has different roles in different cancers. Here, we aims to unravel the novel functions of RPL11 in non-small cell lung cancer (NSCLC), especially that affecting cell proliferation. Methods Expression level of RPL11 in different NSCLC cell lines was detected using western blotting. The function of RPL11 in NSCLC cells were CCK-8, colony formation and scratch wound healing detected. Mechanisms of RPL11 on NSCLC cells proliferation were explored by flow cytometry, autophagy detection, and usage of an autophagy inhibitor chloroquine (CQ) and ERS inhibitor (TUDCA) . Results We found that RPL11 was highly expressed in NSCLC cells. Additionally, RPL11 overexpression promoted NSCLC cells proliferation and migration in vitro, and promoted the transition from G1 phase to S phase of the cell cycle. Conversely, RPL11 inhibition suppressed NSCLC cell proliferation and migration, and arrested the cell cycle in G0/G1 phase. Moreover, RPL11 promotes NSCLC cell proliferation via modulating autophagy and ERS. Expression levels of autophagy and ERS markers were induced by RPL11 overexpression, and inhibited by siRPL11. Usage of an autophagy inhibitor chloroquine (CQ) partially reverse the promotion of RPL11 on NSCLC cells proliferation. Besides, RPL11 induced autophagy markers expression could partially reversed by the ERS inhibitor (TUDCA). Conclusions Taken together, RPL11 has a tumor-promoting role in non-small cell lung cancer. It promote the cell proliferation of NSCLC cells by regulating ERS and autophagy.
- 12 December 2022
- Published by Springer Nature in Research Square
Open AccessRPL11 promotes non-small cell lung cancer cell proliferation via regulating endoplasmic reticulum stress and cell autophagy
Background Abnormal ribosomal proteins (RPs) biogenesis and function works importantly in tumorigenesis and development. RPL11 is a component of ribosomal 60S large subunit has different roles in different cancers. Here, we aims to unravel the novel functions of RPL11 in non-small cell lung cancer (NSCLC), especially that affecting cell proliferation. Methods Expression level of RPL11 in different NSCLC cell lines was detected using western blotting. The function of RPL11 in NSCLC cells were CCK-8, colony formation and scratch wound healing detected. Mechanisms of RPL11 on NSCLC cells proliferation were explored by flow cytometry, autophagy detection, and usage of an autophagy inhibitor chloroquine (CQ) and ERS inhibitor (TUDCA) . Results We found that RPL11 was highly expressed in NSCLC cells. Additionally, RPL11 overexpression promoted NSCLC cells proliferation and migration in vitro, and promoted the transition from G1 phase to S phase of the cell cycle. Conversely, RPL11 inhibition suppressed NSCLC cell proliferation and migration, and arrested the cell cycle in G0/G1 phase. Moreover, RPL11 promotes NSCLC cell proliferation via modulating autophagy and ERS. Expression levels of autophagy and ERS markers were induced by RPL11 overexpression, and inhibited by siRPL11. Usage of an autophagy inhibitor chloroquine (CQ) partially reverse the promotion of RPL11 on NSCLC cells proliferation. Besides, RPL11 induced autophagy markers expression could partially reversed by the ERS inhibitor (TUDCA). Conclusions Taken together, RPL11 has a tumor-promoting role in non-small cell lung cancer. It promote the cell proliferation of NSCLC cells by regulating ERS and autophagy.